ArriVent BioPharma, Inc. Common Stock
AVBP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $838,343 | $639,133 | $669,875 | $25,520 |
| - Cash | $74,293 | $150,389 | $163,372 | $37,280 |
| + Debt | $176 | $317 | $139 | $0 |
| Enterprise Value | $764,226 | $489,061 | $506,642 | -$11,760 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$80,488 | -$74,590 | $0 | -$51,606 |
| % Margin | – | – | – | – |
| Net Income | -$80,488 | -$69,333 | -$36,906 | -$51,606 |
| % Margin | – | – | – | – |
| EPS Diluted | -2.56 | -2.17 | -1.1 | -40.44 |
| % Growth | -18% | -97.3% | 97.3% | – |
| Operating Cash Flow | -$70,212 | -$55,842 | -$43,631 | -$12,587 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$70,212 | -$55,842 | -$43,631 | -$12,587 |